BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38553264)

  • 1. Evaluation of URO17® to improve non-invasive detection of bladder cancer.
    Porten SP; Wang EY; Vohra P; Carroll PR; Jahanfard S; Kim NW
    Urol Oncol; 2024 Jun; 42(6):176.e21-176.e28. PubMed ID: 38553264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of URO17® in diagnosis and follow up of bladder cancer patients.
    Ibrahim M; Rabinowitz J; Hilbert R; Ghose A; Agarwal S; Swamy R; Bulut I; Guttierrez M; Buali E; Nassar E; Jhavar P; Al-Hashimi F; Vasdev N
    BMC Urol; 2024 Feb; 24(1):34. PubMed ID: 38336681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.
    Davis N; Shtabsky A; Lew S; Rona R; Leibovitch I; Nativ O; Cohen M; Mor Y; Lindner U; Glickman Y; Matzkin H; Tsivian A; Gofrit O; Yossepovitch O
    Eur Urol Focus; 2018 Apr; 4(3):388-394. PubMed ID: 28753799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of semaphorin 3A in patients with urothelial cancer.
    Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
    Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.
    Sawczuk IS; Pickens CL; Vasa UR; Ralph DA; Norris KA; Miller MC; Ng AY; Grossman HB; Veltri RW
    Urol Oncol; 2002; 7(5):185-90. PubMed ID: 12644214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
    Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
    Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.
    Frantzi M; van Kessel KE; Zwarthoff EC; Marquez M; Rava M; Malats N; Merseburger AS; Katafigiotis I; Stravodimos K; Mullen W; Zoidakis J; Makridakis M; Pejchinovski M; Critselis E; Lichtinghagen R; Brand K; Dakna M; Roubelakis MG; Theodorescu D; Vlahou A; Mischak H; Anagnou NP
    Clin Cancer Res; 2016 Aug; 22(16):4077-86. PubMed ID: 27026199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of bladder cancer using a point-of-care proteomic assay.
    Grossman HB; Messing E; Soloway M; Tomera K; Katz G; Berger Y; Shen Y
    JAMA; 2005 Feb; 293(7):810-6. PubMed ID: 15713770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor.
    Retz M; Lehmann J; Amann E; Wullich B; Röder C; Stöckle M
    J Urol; 2003 Jan; 169(1):86-9. PubMed ID: 12478110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
    Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
    JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of CellDetect for detection of bladder cancer: Comparison with urine cytology and UroVysion.
    Shefer HK; Masarwe I; Bejar J; Naamnih LH; Gueta-Milshtein K; Shalata A; Hadid Y; Nativ O; Nativ O
    Urol Oncol; 2023 Jun; 41(6):296.e1-296.e8. PubMed ID: 36642638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
    BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis.
    Babu S; Kim NW; Wu M; Chan I; Escobar-Hoyos LF; Shroyer KR
    Am J Clin Pathol; 2021 Oct; 156(5):926-933. PubMed ID: 34086841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.
    Odisho AY; Berry AB; Ahmad AE; Cooperberg MR; Carroll PR; Konety BR
    Eur Urol; 2013 May; 63(5):936-40. PubMed ID: 22521093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.